Literature DB >> 20700043

FK228 and oncogenic H-Ras synergistically induce Mek1/2 and Nox-1 to generate reactive oxygen species for differential cell death.

Shambhunath Choudhary1, Kusum Rathore, Hwa-Chain Robert Wang.   

Abstract

To investigate the mechanism behind the pro-apoptotic ability of oncogenic H-Ras to enhance FK228-induced apoptosis, we primarily used the 10T1/2-TR-H-Ras cell line, in which ectopic expression of oncogenic H-Ras(V12) is controlled by the addition of tetracycline into cultures, and secondarily used oncogenic H-Ras-expressing MCF10A cells in our studies. Our results showed the pro-apoptotic roles of Mek1/2 activation, nicotinamide adenine dinucleotide phosphate-oxidase 1 (Nox-1) elevation, and reactive oxygen species (ROS) production in FK228-induced selective cell death of oncogenic H-Ras-expressing cells versus counterpart cells. We found that although Nox-1 elevation and ROS production played essential roles in oncogenic H-Ras-induced cell proliferation and morphological transformation, the expression of oncogenic H-Ras and FK228 treatment synergistically induced activation of Mek1/2. This activation resulted in differentially increased Nox-1 elevation and ROS production leading to selective cell death of oncogenic H-Ras-expressing cells versus counterpart cells. We also found that FK228 treatment induced mitochondrial ROS and Mek1/2 activation, bypassing Raf-1, to downstream Erk1/2, participating in the induction of selective cell death. Thus, the pro-apoptotic abilities of Mek1/2 and Nox-1 should be considered as potential targets in designing therapeutic protocols using FK228 to assure ROS-mediated cell death for treating cancer cells acquiring Ras activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20700043     DOI: 10.1097/CAD.0b013e32833ddba6

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

1.  Intervention of human breast cell carcinogenesis chronically induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Authors:  Shambhunath Choudhary; Shilpa Sood; Robert L Donnell; Hwa-Chain R Wang
Journal:  Carcinogenesis       Date:  2012-02-03       Impact factor: 4.944

Review 2.  Reactive oxygen species-mediated therapeutic control of bladder cancer.

Authors:  Hwa-Chain R Wang; Shambhunath Choudhary
Journal:  Nat Rev Urol       Date:  2011-10-04       Impact factor: 14.432

3.  Mesenchymal and stem-like cell properties targeted in suppression of chronically-induced breast cell carcinogenesis.

Authors:  Kusum Rathore; Hwa-Chain Robert Wang
Journal:  Cancer Lett       Date:  2013-01-22       Impact factor: 8.679

4.  The Interplay between ROS and Ras GTPases: Physiological and Pathological Implications.

Authors:  Elisa Ferro; Luca Goitre; Saverio Francesco Retta; Lorenza Trabalzini
Journal:  J Signal Transduct       Date:  2011-11-30

Review 5.  Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer.

Authors:  Siddhartha Das Pramanik; Amit Kumar Halder; Ushmita Mukherjee; Dharmendra Kumar; Yadu Nandan Dey; Mogana R
Journal:  Front Chem       Date:  2022-08-12       Impact factor: 5.545

6.  A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.

Authors:  Pawat Pattarawat; Jessica T Hunt; Jacob Poloway; Collin J Archibald; Hwa-Chain Robert Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-05-27       Impact factor: 3.288

7.  Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.

Authors:  Pawat Pattarawat; Tian Hong; Shelby Wallace; Yanchun Hu; Robert Donnell; Tzu-Hao Wang; Chia-Lung Tsai; Jinquan Wang; Hwa-Chain Robert Wang
Journal:  Br J Cancer       Date:  2020-05-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.